Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Erica L Jackson

6PUBLICATIONS
63CO-AUTHORS
Molecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

Sort by Publication Date:
|Jun 04, 2025
STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models.

Raymond A Pagliarini, Jack A Henderson, Benjamin C Milgram

|Aug 23, 2024
ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors.

Christopher T Chen, Vishesh Khanna, Shivaani Kummar

|Sep 15, 2023
Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science.

Darrin D Stuart, Angel Guzman-Perez, Natasja Brooijmans

|Aug 25, 2023
STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts.

Leonard Buckbinder, David J St Jean, Trang Tieu

|Aug 19, 2022
EHMT2 methyltransferase governs cell identity in the lung and is required for KRAS <sup>G12D</sup> tumor development and propagation.

Ariel Pribluda, Anneleen Daemen, Anthony Nelson Lima

|May 31, 2019
NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma.

Ganapati V Hegde, Cecile de la Cruz, Jennifer M Giltnane

Pageof 1

Frequent Collaborators

3 joint publications

Angel Guzman-Perez

3 joint publications

Darrin D Stuart

3 joint publications

Natasja Brooijmans

3 joint publications

Gregory V Kryukov

2 joint publications

Michael R Huff

2 joint publications

Anneleen Daemen

2 joint publications

Melissa R Junttila

2 joint publications

Brendon Ladd

2 joint publications

Brendan J Hilbert

2 joint publications

Weixue Wang

Frequent Collaborators

3 joint publications

Angel Guzman-Perez

3 joint publications

Darrin D Stuart

3 joint publications

Natasja Brooijmans

3 joint publications

Gregory V Kryukov

Top Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

7.4K
High-Throughput <em>In Vitro</em> Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput <em>In Vitro</em> Assay using Patient-Derived Tumor Organoids

Published on : Jun 14, 2021

5.3K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on : Apr 11, 2016

11.9K
See more related videos

Top Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

7.4K
High-Throughput <em>In Vitro</em> Assay using Patient-Derived Tumor Organoids
06:25

High-Throughput <em>In Vitro</em> Assay using Patient-Derived Tumor Organoids

Published on : Jun 14, 2021

5.3K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on : Apr 11, 2016

11.9K
See more related videos